Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

Abstract

Background. Pharmaco-dynamic separation of cytotoxic and targeted drugs might avoid their mutual antagonistic effect in the treatment of advanced non-small cell lung cancer (NSCLC).

Keywords

• non-small cell lung cancer
• egfr activating mutations
• gemcitabine
• cisplatin
• erlotinib
• intercalated therapy
• metabolic response